Pipeline
Our pipeline is focused on half-life extended T cell engager drug opportunities across a broad range of solid tumors as well as autoimmune indications
Novel targets
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
BA211
Dual-indication*
> 10,000
HLA-A2+
TC11
αCD3 TCE
DC Selection
DC Selection
IND
IND
2025
2025
2026
2026
BA2168
Multi-indication*
> 60,000
HLA-A2+
TC168
αCD3 TCE
DC Selection
DC Selection
IND
IND
2026
2026
2027
2027
BA225
Multi-indication*
> 60,000
HLA-A2+
TC25
Undisclosed
DC Selection
DC Selection
IND
IND
2026
2026
2027
2027
Multiple
> 60,000
Pan-HLA+
Undisclosed
Lead selection
Lead selection
*High potential indications including MSS CRC, Gastric, Oesophageal (Sq./Ad), Lung (Sq/Ad), Melanoma, HNSCC, Bladder, Pancreatic
Autoimmune
program
BA301
Multi-indication
Autoimmune
Not HLA-restricted
TC301
Undisclosed
Lead selection
Lead selection
Other targets
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
BA201
BA202
BA2401
20,000-40,000
MAGE-A4/A8
PRAME A2
PRAME A24
DC Selection
DC Selection
2026
2026
Novel targets
BA211
Dual-indication*
DC Selection
IND
2026
DC 2025
2025
2027
IND 2026
2026
> 10,000
HLA-A2+ US patients
> 10,000
HLA-A2+
> 10,000
HLA-A2+
TC11
αCD3 TCE
Annual addressable metastatic patients
Annual addressable metastatic US patients
Target and engager
Solid tumor program
Pipeline
Pipeline
Our pipeline is focused on half-life extended T cell engager drug opportunities across a broad range of solid tumours as well as autoimmune indications
Our pipeline is focused on half-life extended T cell engager drug opportunities across a broad range of solid tumors as well as autoimmune indications
Our pipeline is focused on half-life extended T cell engager drug opportunities across a broad range of solid tumors as well as autoimmune indications
BA2168
Multi-indication*
DC Selection
IND
2026
DC 2026
2026
2027
IND 2027
2027
> 60,000
HLA-A2+ US patients
> 60,000
HLA-A2+
> 60,000
HLA-A2+
TC168
αCD3 TCE
Annual addressable metastatic patients
Annual addressable metastatic US patients
Annual addressable metastatic US patients
Target and engager
Target and engager
Solid tumor program
Other targets
Other targets
BA201
BA202
BA2401
DC Selection
2026
DC 2026
2026
20-40k US patients
20,000-40,000
20,000-40,000
MAGE-A4/A8 HLA-A2
PRAME HLA-A2
PRAME HLA-A24
MAGE-A4/A8
PRAME A2
PRAME A24
MAGE-A4/A8
PRAME A2
PRAME A24
Annual addressable metastatic patients
Annual addressable metastatic US patients
Annual addressable metastatic US patients
Target and engager
Solid tumor program
BA225
Multi-indication*
DC Selection
IND
2026
DC 2026
2026
2027
IND 2027
2027
> 60,000
HLA-A2+ US patients
> 60,000
HLA-A2+
> 60,000
HLA-A2+
TC25
Undisclosed
Annual addressable metastatic patients
Annual addressable metastatic US patients
Annual addressable metastatic US patients
Target and engager
Target and engager
Solid tumor program
BA301
Multi-indication
Lead selection
Lead selection
Lead selection
Autoimmune
Not HLA-restricted
TC301
Undisclosed
Annual addressable metastatic patients
Annual addressable metastatic US patients
Annual addressable metastatic US patients
Target and engager
Target and engager
Autoimmune program
Multiple
Lead selection
Lead selection
Lead selection
> 60,000
HLA-A2+ US patients
> 60,000
HLA-A2+
> 60,000
HLA-A2+
Undisclosed
Annual addressable metastatic patients
Annual addressable metastatic US patients
Annual addressable metastatic US patients
Target and engager
Target and engager
Solid tumor program
*High potential indications for TCEs including MSS CRC, Gastric, Oesophageal (Sq./Ad), Lung (Sq/Ad), Melanoma, HNSCC, Bladder, Pancreatic
*High potential indications including MSS CRC, Gastric, Oesophageal (Sq./Ad), Lung (Sq/Ad), Melanoma, HNSCC, Bladder, Pancreatic
*High potential indications including MSS CRC, Gastric, Oesophageal (Sq./Ad), Lung (Sq/Ad), Melanoma, HNSCC, Bladder, Pancreatic